{
    "relation": [
        [
            "Company",
            "PGT INC",
            "MITEK SYSTE\u2026",
            "LAWSON PROD\u2026",
            "AMEDISYS IN\u2026",
            "DOT HILL SY\u2026"
        ],
        [
            "Symbol",
            "PGTI",
            "MITK",
            "LAWS",
            "AMED",
            "HILL"
        ],
        [
            "Price",
            "16.07",
            "3.62",
            "27.36",
            "43.63",
            "6.32"
        ],
        [
            "%Chg",
            "+4.15%",
            "+3.13%",
            "+2.36%",
            "+2.06%",
            "+1.77%"
        ]
    ],
    "pageTitle": "Current Decline in Share Price is an Opportunity to Accumulate Shares - February 14, 2013 - Zacks.com",
    "title": "",
    "url": "http://www.zacks.com/stock/news/92744/current-decline-in-share-price-is-an-opportunity-to-accumulate-shares",
    "hasHeader": true,
    "headerPosition": "FIRST_ROW",
    "tableType": "RELATION",
    "tableNum": 0,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042989126.22/warc/CC-MAIN-20150728002309-00294-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 858512547,
    "recordOffset": 858491301,
    "tableOrientation": "HORIZONTAL",
    "TableContextTimeStampAfterTable": "{63807=Copyright \u00a9 2015 Zacks Investment Research, 22140=This presentation by invitation from EMIT describes the mechanistic foundation for Novelos\u2019 diapeutic (diagnostic + therapeutic) technology platform together with animal data and initial findings in advanced cancer patients that demonstrate selective and prolonged accumulation of Novelos\u2019 PET imaging I-124-CLR1404 (LIGHT), therapeutic I-131-CLR1404 (HOT) and optical imaging CLR1502 (GLOW2) compounds in a range of tumor types. The presenter is Dr. Chris Pazoles, who is the Senior Vice President of Research and Development for Novelos., 20768=On Nov. 5, 2012, Novelos announced the closing of a private placement of equity securities to an affiliated entity of Renova Group for gross proceeds to Novelos of $2 million.\u00a0 Novelos has earmarked the proceeds for the build-out of an in-house clinical-stage manufacturing facility for I-124-CLR1404 (LIGHT).\u00a0 The facility is expected to be completed in about one year and is expected to cost approximately $3 million. The build-out of an in-house clinical-stage manufacturing facility for LIGHT is a key strategic initiative as the Company moves toward larger Phase II and pivotal LIGHT imaging trials.\u00a0NVLT already has an operational in-house clinical-stage manufacturing facility for HOT., 63868=At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm., 14751=\u00a0\u00a0Published on February 14, 2013 |, 19580=On February 13, 2013, Novelos Therapeutics (OTC Markets:) announced the pricing of a public offering of 11,000,000 units at $0.50 per unit for gross proceeds of $5,500,000.\u00a0 Click here to download a free copy of the NVLT research report: NVLT 2-13-13, 21887=On January 31, 2013, Novelos Therapeutics presented an oral presentation on research conducted by Novelos and its collaborators at the EMIT: Targeted Radiotherapy international conference taking place January 29 to 31, in Washington, D.C., 20536=At the end of September 2012, NVLT had cash and cash equivalents of $5.6 million. With the $5.5 million gross proceeds, the Company should have about $6.5 million in cash as of today. Current cash will last into 3Q13.}",
    "lastModified": "Sun, 02 Aug 2015 09:59:47 -0500",
    "textBeforeTable": "Income Momentum Value Growth Zacks #1 Rank Top Movers for Aug 2, 2015 Zacks #1 Rank Top Movers Zacks #1 Rank Top Movers for 08/02/15 } } document.getElementById('score_val').className = ''; document.getElementById('score_val').innerHTML = ''; document.getElementById('tab_label').innerHTML = tab_text; { else } document.getElementById('score_val').className = 'scores_val'; document.getElementById('score_val').innerHTML = 'A'; document.getElementById('tab_label').innerHTML = tab_text+ ' Score'; { if(tab_text != 'income') document.getElementById('rank_text').innerHTML = cat_uri; var cat_uri = 'View All Zacks Rank #1 '+tab_text+' Stocks'; var cat_uri = '/stocks/buy-list/'+tab_text; { function footer_text(tab_text)",
    "textAfterTable": "Company Symbol Price %Chg SKYWEST INC\u2026 SKYW 16.56 +18.37% NCI INC-CL\u2026 NCIT 11.25 +11.61% MARCUS CORP\u2026 MCS 20.96 +2.69% UPM-KYMMENE\u2026 UPMKY 18.42 +1.88% SYKES ENTRP\u2026 SYKE 24.38 +1.75% Company Symbol Price %Chg ELLIE MAE I\u2026 ELLI 78.45 +13.48% GIGOPTIX IN\u2026 GIG 2.34 +4.93% AMEDISYS IN\u2026 AMED 43.63 +2.06% COTT CORP Q\u2026 COT 11.24 +1.35%",
    "hasKeyColumn": true,
    "keyColumnIndex": 0,
    "headerRowIndex": 0
}